;PMID: 9537203 ;source_file_1306.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..38] = [t:0..38] ;1)sentence:[e:43..165] = [t:43..165] ;2)section:[e:169..281] = [t:169..281] ;3)section:[e:285..325] = [t:285..325] ;4)sentence:[e:329..544] = [t:329..544] ;5)sentence:[e:545..691] = [t:545..691] ;6)sentence:[e:692..761] = [t:692..761] ;7)sentence:[e:762..844] = [t:762..844] ;8)sentence:[e:845..938] = [t:845..938] ;9)sentence:[e:939..1030] = [t:939..1030] ;10)sentence:[e:1031..1297] = [t:1031..1297] ;11)sentence:[e:1298..1362] = [t:1298..1362] ;12)sentence:[e:1363..1537] = [t:1363..1537] ;13)section:[e:1541..1585] = [t:1541..1585] ;section 0 Span:0..38 ;Am J Clin Oncol 1998 Apr;21(2):155-60 (SEC (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NNP:[5..9] Clin) (NNP:[10..15] Oncol) (CD:[17..21] 1998) (.:[22..29] Apr;21-LRB-) (CD:[29..30] 2) (-RRB-:[30..31] -RRB-) (CD:[31..35] :155) (CD:[35..38] -60))) ;sentence 1 Span:43..165 ;Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 ;oncoprotein expression in adenocarcinoma of the lung. ;[63..68]:gene-rna:"K-ras" ;[80..83]:gene-protein:"ras" ;[101..110]:gene-protein:"c-erb B-2" ;[138..164]:malignancy-type:"adenocarcinoma of the lung" (SENT (NP-HLN (NP (JJ:[43..53] Prognostic) (NN:[54..59] value)) (PP (IN:[60..62] of) (NP (NP (NN:[63..68] K-ras) (NNS:[69..78] mutations)) (,:[78..79] ,) (NP (NN:[80..83] ras) (NN:[84..95] oncoprotein)) (,:[95..96] ,) (CC:[97..100] and) (NP (NML (NN:[101..106] c-erb) (NN:[107..110] B-2)) (NN:[111..122] oncoprotein) (NN:[124..134] expression)))) (PP (IN:[135..137] in) (NP (NP (NN:[138..152] adenocarcinoma)) (PP (IN:[153..155] of) (NP (DT:[156..159] the) (NN:[160..164] lung))))) (.:[164..165] .))) ;section 2 Span:169..281 ;Nemunaitis J, Klemow S, Tong A, Courtney A, Johnston W, Mack M, Taylor W, ;Solano M, Stone M, Mallams J, Mues G. (SEC (FRAG (NNP:[169..179] Nemunaitis) (NNP:[180..182] J,) (NNP:[183..189] Klemow) (NNP:[190..191] S) (,:[191..192] ,) (NNP:[193..197] Tong) (NNP:[198..199] A) (,:[199..200] ,) (NNP:[201..209] Courtney) (NNP:[210..211] A) (,:[211..212] ,) (NNP:[213..221] Johnston) (NNP:[222..223] W) (,:[223..224] ,) (NNP:[225..229] Mack) (NNP:[230..232] M,) (NNP:[233..239] Taylor) (NNP:[240..241] W) (,:[241..242] ,) (NNP:[243..249] Solano) (NNP:[251..253] M,) (NNP:[254..259] Stone) (NNP:[260..262] M,) (NNP:[263..270] Mallams) (NNP:[271..273] J,) (NNP:[274..278] Mues) (NNP:[279..281] G.))) ;section 3 Span:285..325 ;Texas Oncology, P.A., Dallas 75246, USA. (SEC (FRAG (NNP:[285..290] Texas) (NNP:[291..299] Oncology) (,:[299..300] ,) (NNP:[301..305] P.A.) (,:[305..306] ,) (NNP:[307..313] Dallas) (CD:[314..319] 75246) (,:[319..320] ,) (NNP:[321..324] USA) (.:[324..325] .))) ;sentence 4 Span:329..544 ;This trial was undertaken to determine the prognostic role of K-ras (p21), ;c-erb B-2 (p185) protein expression, and the presence or nonpresence of a ;K-ras gene mutation in patients with adenocarcinoma of the lung. ;[391..396]:gene-protein:"K-ras" ;[398..401]:gene-protein:"p21" ;[404..414]:gene-protein:"c-erb B-2" ;[416..420]:gene-protein:"p185" ;[479..484]:gene-rna:"K-ras" ;[517..543]:malignancy-type:"adenocarcinoma of the lung" (SENT (S (NP-SBJ-1 (DT:[329..333] This) (NN:[334..339] trial)) (VP (VBD:[340..343] was) (VP (VBN:[344..354] undertaken) (NP-1 (-NONE-:[354..354] *)) (S-PRP (NP-SBJ (-NONE-:[354..354] *)) (VP (TO:[355..357] to) (VP (VB:[358..367] determine) (NP (NP (DT:[368..371] the) (JJ:[372..382] prognostic) (NN:[383..387] role)) (PP (IN:[388..390] of) (NP (NP (NN:[391..396] K-ras) (PRN (-LRB-:[397..398] -LRB-) (NP (NN:[398..401] p21)) (-RRB-:[401..402] -RRB-))) (,:[402..403] ,) (NP (NML (NN:[404..409] c-erb) (NN:[411..414] B-2) (NML (-LRB-:[415..416] -LRB-) (NN:[416..420] p185) (-RRB-:[420..421] -RRB-))) (NN:[422..429] protein) (NN:[430..440] expression)) (,:[440..441] ,) (CC:[442..445] and) (NP (NP (DT:[446..449] the) (NN:[450..458] presence) (CC:[459..461] or) (NN:[462..473] nonpresence)) (PP (IN:[474..476] of) (NP (DT:[477..478] a) (NN:[479..484] K-ras) (NN:[485..489] gene) (NN:[491..499] mutation)))))) (PP-LOC (IN:[500..502] in) (NP (NP (NNS:[503..511] patients)) (PP (IN:[512..516] with) (NP (NP (NN:[517..531] adenocarcinoma)) (PP (IN:[532..534] of) (NP (DT:[535..538] the) (NN:[539..543] lung))))))))))))) (.:[543..544] .))) ;sentence 5 Span:545..691 ;This was a retrospective study of 103 patients with adeno- or large-cell ;carcinoma of the lung who had available paraffin-stored tumor material. ;[598..604]...[614..640]:malignancy-type:"adeno-"..."cell carcinoma of the ;lung" ;[608..640]:malignancy-type:"large-cell carcinoma of the lung" (SENT (S (NP-SBJ (DT:[545..549] This)) (VP (VBD:[550..553] was) (NP-PRD (NP (DT:[554..555] a) (JJ:[556..569] retrospective) (NN:[571..576] study)) (PP (IN:[577..579] of) (NP (NP (NP (CD:[580..583] 103) (NNS:[584..592] patients)) (PP (IN:[593..597] with) (NP (NP (NP (AFX:[598..603] adeno) (HYPH:[603..604] -) (NML-1 (-NONE-:[604..604] *P*))) (CC:[605..607] or) (NP (NML (JJ:[608..613] large) (HYPH:[613..614] -) (NN:[614..618] cell)) (NML-1 (NN:[619..628] carcinoma)))) (PP (IN:[629..631] of) (NP (DT:[632..635] the) (NN:[636..640] lung)))))) (SBAR (WHNP-2 (WP:[641..644] who)) (S (NP-SBJ-2 (-NONE-:[644..644] *T*)) (VP (VBD:[645..648] had) (NP (JJ:[650..659] available) (ADJP (NN:[660..668] paraffin) (HYPH:[668..669] -) (VBN:[669..675] stored)) (NN:[676..681] tumor) (NN:[682..690] material))))))))) (.:[690..691] .))) ;sentence 6 Span:692..761 ;The relation of several clinical variables to survival was analyzed. (SENT (S (NP-SBJ-1 (NP (DT:[692..695] The) (NN:[696..704] relation)) (PP (IN:[705..707] of) (NP (JJ:[708..715] several) (JJ:[716..724] clinical) (NNS:[726..735] variables))) (PP (TO:[736..738] to) (NP (NN:[739..747] survival)))) (VP (VBD:[748..751] was) (VP (VBN:[752..760] analyzed) (NP-1 (-NONE-:[760..760] *)))) (.:[760..761] .))) ;sentence 7 Span:762..844 ;Immunohistochemical techniques were used to determine expression of p21 and ;p185. ;[831..834]:gene-protein:"p21" ;[839..843]:gene-protein:"p185" (SENT (S (NP-SBJ-1 (JJ:[762..781] Immunohistochemical) (NNS:[782..792] techniques)) (VP (VBD:[793..797] were) (VP (VBN:[798..802] used) (NP-1 (-NONE-:[802..802] *)) (S-PRP (NP-SBJ (-NONE-:[802..802] *)) (VP (TO:[803..805] to) (VP (VB:[807..816] determine) (NP (NP (NN:[817..827] expression)) (PP (IN:[828..830] of) (NP (NP (NN:[831..834] p21)) (CC:[835..838] and) (NP (NN:[839..843] p185)))))))))) (.:[843..844] .))) ;sentence 8 Span:845..938 ;Polymerase chain reaction (PCR) and sequencing were used to determine K-ras ;mutation status. ;[845..855]:gene-protein:"Polymerase" ;[916..921]:gene-rna:"K-ras" (SENT (S (NP-SBJ-1 (NP (NP (NN:[845..855] Polymerase) (NN:[856..861] chain) (NN:[862..870] reaction)) (NP (-LRB-:[871..872] -LRB-) (NN:[872..875] PCR) (-RRB-:[875..876] -RRB-))) (CC:[877..880] and) (NP (NN:[882..892] sequencing))) (VP (VBD:[893..897] were) (VP (VBN:[898..902] used) (NP-1 (-NONE-:[902..902] *)) (S-PRP (NP-SBJ (-NONE-:[902..902] *)) (VP (TO:[903..905] to) (VP (VB:[906..915] determine) (NP (NN:[916..921] K-ras) (NN:[922..930] mutation) (NN:[931..937] status))))))) (.:[937..938] .))) ;sentence 9 Span:939..1030 ;Tumor stage was the only nonmolecular clinical variable predictive of ;survival (p=0.0001). (SENT (S (NP-SBJ (NN:[939..944] Tumor) (NN:[945..950] stage)) (VP (VBD:[951..954] was) (NP-PRD (NP (DT:[955..958] the) (JJ:[960..964] only) (JJ:[965..977] nonmolecular) (JJ:[978..986] clinical) (NN:[987..995] variable)) (ADJP (JJ:[996..1006] predictive) (PP (IN:[1007..1009] of) (NP (NN:[1010..1018] survival))) (PRN (-LRB-:[1019..1020] -LRB-) (S (NP-SBJ (NN:[1020..1021] p)) (VP (SYM:[1021..1022] =) (NP (CD:[1022..1028] 0.0001)))) (-RRB-:[1028..1029] -RRB-))))) (.:[1029..1030] .))) ;sentence 10 Span:1031..1297 ;A combination of K-ras mutation and p 185 expression (p=0.0144), ras ;mutation and strong p21 expression (p=0.0137), and K-ras mutation and the ;combined expression of p21 and p185 were predictive of poor survival ;(p=0.0415) in univariate analysis of all patients. ;[1049..1054]:gene-rna:"K-ras" ;[1068..1073]:gene-protein:"p 185" ;[1097..1100]:gene-rna:"ras" ;[1122..1125]:gene-protein:"p21" ;[1153..1158]:gene-rna:"K-ras" ;[1200..1203]:gene-protein:"p21" ;[1208..1212]:gene-protein:"p185" (SENT (S (NP-SBJ (NP (DT:[1031..1032] A) (NN:[1034..1045] combination)) (PP (IN:[1046..1048] of) (NP (NP (NP (NN:[1049..1054] K-ras) (NN:[1055..1063] mutation)) (CC:[1064..1067] and) (NP (NML (NN:[1068..1069] p) (CD:[1070..1073] 185)) (NN:[1074..1084] expression)) (PRN (-LRB-:[1085..1086] -LRB-) (S (NP-SBJ (NN:[1086..1087] p)) (VP (SYM:[1087..1088] =) (NP (CD:[1088..1094] 0.0144)))) (-RRB-:[1094..1095] -RRB-))) (,:[1095..1096] ,) (NP (NP (NN:[1097..1100] ras) (NN:[1101..1109] mutation)) (CC:[1110..1113] and) (NP (JJ:[1115..1121] strong) (NN:[1122..1125] p21) (NN:[1126..1136] expression)) (PRN (-LRB-:[1137..1138] -LRB-) (S (NP-SBJ (NN:[1138..1139] p)) (VP (SYM:[1139..1140] =) (NP (CD:[1140..1146] 0.0137)))) (-RRB-:[1146..1147] -RRB-))) (,:[1147..1148] ,) (CC:[1149..1152] and) (NP (NP (NN:[1153..1158] K-ras) (NN:[1159..1167] mutation)) (CC:[1168..1171] and) (NP (NP (DT:[1172..1175] the) (VBN:[1176..1184] combined) (NN:[1185..1195] expression)) (PP (IN:[1197..1199] of) (NP (NP (NN:[1200..1203] p21)) (CC:[1204..1207] and) (NP (NN:[1208..1212] p185))))))))) (VP (VBD:[1213..1217] were) (ADJP-PRD (JJ:[1218..1228] predictive) (PP (IN:[1229..1231] of) (NP (JJ:[1232..1236] poor) (NN:[1237..1245] survival))) (PRN (-LRB-:[1246..1247] -LRB-) (S (NP-SBJ (NN:[1247..1248] p)) (VP (SYM:[1248..1249] =) (NP (CD:[1249..1255] 0.0415)))) (-RRB-:[1255..1256] -RRB-))) (PP (IN:[1257..1259] in) (NP (NP (JJ:[1260..1270] univariate) (NN:[1272..1280] analysis)) (PP (IN:[1281..1283] of) (NP (DT:[1284..1287] all) (NNS:[1288..1296] patients)))))) (.:[1296..1297] .))) ;sentence 11 Span:1298..1362 ;The sole presence of K-ras mutation was predictive of survival. ;[1319..1324]:gene-rna:"K-ras" (SENT (S (NP-SBJ (NP (DT:[1298..1301] The) (JJ:[1302..1306] sole) (NN:[1307..1315] presence)) (PP (IN:[1316..1318] of) (NP (NN:[1319..1324] K-ras) (NN:[1325..1333] mutation)))) (VP (VBD:[1334..1337] was) (ADJP-PRD (JJ:[1338..1348] predictive) (PP (IN:[1349..1351] of) (NP (NN:[1353..1361] survival))))) (.:[1361..1362] .))) ;sentence 12 Span:1363..1537 ;Additionally, when combined with elevated p21 or p185 expression in a subset ;of patients with 4 or more years of follow-up, negative correlation with ;survival was observed. ;[1405..1408]:gene-protein:"p21" ;[1412..1416]:gene-protein:"p185" (SENT (S (ADVP (RB:[1363..1375] Additionally)) (,:[1375..1376] ,) (SBAR (WHADVP-2 (WRB:[1377..1381] when)) (S (NP-SBJ (-NONE-:[1381..1381] *)) (VP (VBN:[1382..1390] combined) (PP-CLR (IN:[1391..1395] with) (NP (ADJP (VBN:[1396..1404] elevated)) (NML (NML (NN:[1405..1408] p21) (NML-1 (-NONE-:[1408..1408] *P*))) (CC:[1409..1411] or) (NML (NN:[1412..1416] p185) (NML-1 (NN:[1417..1427] expression)))))) (PP (IN:[1428..1430] in) (NP (NP (DT:[1431..1432] a) (NN:[1434..1440] subset)) (PP (IN:[1441..1443] of) (NP (NP (NNS:[1444..1452] patients)) (PP (IN:[1453..1457] with) (NP (NP (QP (CD:[1458..1459] 4) (CC:[1460..1462] or) (JJR:[1463..1467] more)) (NNS:[1468..1473] years)) (PP (IN:[1474..1476] of) (NP (VB:[1477..1483] follow) (HYPH:[1483..1484] -) (RP:[1484..1486] up))))))))) (ADVP-TMP-2 (-NONE-:[1486..1486] *T*))))) (,:[1486..1487] ,) (NP-SBJ-3 (NP (JJ:[1488..1496] negative) (NN:[1497..1508] correlation)) (PP (IN:[1509..1513] with) (NP (NN:[1515..1523] survival)))) (VP (VBD:[1524..1527] was) (VP (VBN:[1528..1536] observed) (NP-3 (-NONE-:[1536..1536] *)))) (.:[1536..1537] .))) ;section 13 Span:1541..1585 ;PMID: 9537203 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1541..1545] PMID) (::[1545..1546] :) (CD:[1547..1554] 9537203) (NN:[1555..1556] -LSB-) (NNP:[1556..1562] PubMed) (::[1563..1564] -) (NN:[1565..1572] indexed) (IN:[1573..1576] for) (NNP:[1577..1585] MEDLINE-RSB-)))